Companies › Cell Biopeutics Resources Sdn Bhd
1 active drug program in 2 registered trials: 2 Phase 4; Cardiovascular; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Stempeucel® Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) | – | Phase 4 | Critical Limb Ischemia | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05854641 | Stempeucel® | Phase 4 | Critical Limb Ischemia | Cardiovascular | Oct 2027 |
| NCT05854615 | Stempeucel® | Phase 4 | Critical Limb Ischemia | Cardiovascular | Oct 2027 |
No annotated target.
–
TR Therapeutics Kerecis AOTI Beijing Inno Medicine Nectero Medical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.